BioSpace News Archive

PureTech Health plc today announced the nomination of a new therapeutic candidate, LYT-310, which is an oral cannabidiol (CBD) prodrug and the second therapeutic candidate developed from PureTech’s Glyph™ platform to be advanced toward the clinic. Clinical studies of LYT-310 are expected to begin in Q4 of 2023.

ANANDA Scientific Inc today announced approval by the US Food and Drug Administration (FDA) of the IND application for a clinical trial evaluating Nantheia™ A1002N5S.

Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced the presentation of preclinical data supporting the use of the company’s Nuclear Enriched Sort sequencing (NETSseq) technology platform to identify novel, druggable targets involved in the regulation of neuroinflammation in Alzheimer’s disease (AD).

Wiley will release its second quarter 2023 results prior to market open on Wednesday, December 7, 2022.

Oncotelic Therapeutics, Inc (OTCQB:OTLC) (“Oncotelic”, the “Company” or “We”), a developer of treatments for rare and orphan indications, including Parkinson’s Disease, PDAC, DIPG, and COVID-19, today announced the publication of the presentation materials from the Society for Neuro-Oncology (“SNO”) 27th Annual Meeting held in Tampa Bay, FL on November 16th-20th, 2022 on our website (www.oncotelic.com).

Harrow and iOR Partners today jointly announced the expansion of their national product supply agreement to provide Harrow’s entire formulary compounded ophthalmic products to iOR Partners’ expanding office-based surgery locations across the United States.

Agilent Technologies Inc. (NYSE: A) today announced that it has become the first ‘Angel’ level sponsor of My Green Lab, a nonprofit organization dedicated to building a global culture of sustainability in science.

The Menarini Group will present additional data from the Phase 3 EMERALD study (NCT03778931) of elacestrant, an investigational oral SERD, during the upcoming San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10.

SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will present at the JMP Securities Hematology and Oncology Summit, a virtual investor conference being held from December 6-7, 2022.

Evoke Pharma, Inc. announced the United States Patent and Trademark Office (USPTO) issued a Notice of Allowance for U.S. Application No. 17/100,664 for GIMOTI.